Keyphrases
Arrhythmia
67%
Atrial Fibrillation
59%
Cardiac Resynchronization Therapy
39%
Large Vegetation
38%
Lead Extraction
38%
Cardiac Contractility Modulation
38%
Radiofrequency Catheter Ablation
38%
Atrial Fibrillation Arrhythmia
38%
Collateral Damage
38%
Stellate Ganglion Blockade
38%
Electrical Storm
38%
Acute Myocardial Infarction
38%
Single-center Experience
38%
Vacuum Delivery
38%
Historical Cohort Study
38%
Cardiac Implantable Electronic Device
38%
Diabetes
38%
Management Considerations
38%
Debulking
38%
Ventricular Arrhythmia
38%
Persistent Left Superior Vena Cava (PLSVC)
38%
Acute Decompensated Heart Failure
38%
Pulsed Field Ablation
38%
Watchman Device
38%
Pulmonary Vein Isolation
38%
Symptomatic Atrial Fibrillation
38%
Ejection Fraction
28%
New-onset Atrial Fibrillation
28%
Patients with Diabetes Mellitus
22%
Type 1 Diabetes Mellitus (T1DM)
22%
Guideline-directed Medical Therapy
22%
Defibrillation
21%
Myocardial Infarction
19%
Post-myocardial Infarction
19%
Device Implantation
16%
Hyperglycemia
15%
T-wave Alternans
15%
Myocardium
15%
High Risk
14%
Endocardium
12%
Tachyarrhythmia
12%
Anatomical Structure
12%
Cardiac Conduction
12%
Standard of Care
12%
First-line Therapy
12%
Scar Tissue
12%
Epicardium
12%
Radiofrequency Ablation
12%
Catheter Ablation
12%
Respiratory Support
12%
Medicine and Dentistry
Atrial Fibrillation
76%
Cardiac Resynchronization Therapy
38%
Lead Extraction
38%
Heart Muscle Contractility
38%
Persistent Left Superior Vena Cava
38%
Stellate Ganglion Block
38%
Acute Heart Infarction
38%
Prevalence
38%
Debulking
38%
Cohort Analysis
38%
Pulmonary Vein Isolation
38%
Ablation
38%
Congestive Heart Failure
38%
Ejection Fraction
31%
Myocardial Infarction
30%
Cardiac Dysrhythmia
29%
Apoplexy
26%
New-Onset Atrial Fibrillation
22%
Defibrillation
21%
Antiarrhythmic Agent
16%
Heart Conduction
12%
Radiofrequency Ablation
12%
Tachycardia
12%
Anatomical Concepts
12%
Scar Tissue
12%
Epicardium
12%
Endocardium
12%
Assisted Ventilation
12%
Drug Therapy
12%
Defibrillator
11%
Fluoroscopy
10%
Catheter Ablation
9%
Adverse Event
9%
Device Embolization
9%
Ablation Therapy
9%
Low Drug Dose
9%
Tamponade
9%
Direct Oral Anticoagulant
9%
Patient Population
9%
Dexamethasone
8%
Brain Ischemia
7%
Recurrent Disease
7%
Experimental Therapy
7%
Gene Expression
7%
Clinical Trial
7%
Acute Coronary Syndrome
7%
Coronary Angiography
7%
Percutaneous Coronary Intervention
7%
Combination Therapy
7%
Quality of Life
7%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Arrhythmia
100%
Atrial Fibrillation
76%
Prevalence
38%
Acute Heart Infarction
38%
Antiarrhythmic Agent
38%
Heart Ventricle Arrhythmia
38%
Cohort Study
38%
Diabetes Mellitus
38%
Congestive Heart Failure
38%
Heart Infarction
30%
New-Onset Atrial Fibrillation
22%
Dexamethasone
19%
Randomized Controlled Trial
14%
Ropivacaine
9%
Anticoagulant Agent
9%
Bupivacaine
9%
Hypotension
9%
Local Anesthetic Agent
9%
Hyperglycemia
9%
Lidocaine
9%
Cardiovascular Disease
9%
Acute Coronary Syndrome
7%
Combination Therapy
7%
Recurrent Disease
7%
Clinical Trial
7%
Cardiogenic Shock
7%
Brain Ischemia
7%
Cerebrovascular Accident
7%